Jazz to Acquire Actio Biosciences for Rare Epilepsy Drug
Dublin, Ireland & San Diego, California, USA, August 10, 2026 Jazz Pharmaceuticals plc and Actio Biosciences, Inc. have announced...
Jazz Pharmaceuticals
Advertisement
Jazz and AbCellera Partner on Next-Gen Cancer Antibodies
DUBLIN, Ireland and VANCOUVER, British Columbia, June 17, 2026 Jazz Pharmaceuticals and AbCellera have announced a major strategic collaboration...
Dimerix Licenses DMX-200 to Everest Medicines in Asia
MELBOURNE, Australia, June 16, 2026 Dimerix Limited has announced a landmark exclusive licensing agreement with Everest Medicines for the...
Jazz Presents New Xywav Data at SLEEP 2026 Meeting
DUBLIN, Ireland, June 16, 2026 Jazz Pharmaceuticals plc has unveiled extensive late-breaking research at SLEEP 2026, presenting 11 new...
Jazz Reports Phase 3 LAGOON Results for Zepzelca in SCLC
DUBLIN, Ireland, June 12, 2026 Jazz Pharmaceuticals has announced topline results from the Phase 3 LAGOON trial evaluating Zepzelca®...
Advertisements
Jazz Highlights New Xywav Data Across Narcolepsy and Idiopathic Hypersomnia
DUBLIN, Ireland, June 4, 2026 Jazz Pharmaceuticals has announced the presentation of an extensive portfolio of new clinical and...
Jazz Pharmaceuticals Presents Neurology Drug Data at AAN
DUBLIN, Ireland, April 9, 2026 Jazz Pharmaceuticals plc has announced the presentation of six scientific abstracts, including one oral...
FDA Approves Jazz Pharma’s Zepzelca + Tecentriq Combo for ES-SCLC
DUBLIN, Oct. 2, 2025 – Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that the U.S. Food and Drug Administration...
FDA Adds Modeyso (dordaviprone) to Oncology Guidelines for H3 K27M-Mutant Diffuse Glioma
September 9, 2025 – In a significant advancement for neuro-oncology, Modeyso (dordaviprone) has been included in the National Oncology...
Advertisement
